New antibody drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06547840
First seen Apr 18, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, and then checking if the drug can shrink tumors. About 45 participants will be enrolled to see if the drug is safe and shows promise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bristol Haematology and Oncology Centre
RECRUITINGBristol, BS2 8ED, United Kingdom
-
Cambridge University - Addenbrooke's Hospital
RECRUITINGLondon, CB2 0QQ, United Kingdom
-
Edinburgh Cancer Research Centre
RECRUITINGEdinburgh, EH4 2XR, United Kingdom
-
Guy's Hospital
RECRUITINGLondon, SE1 3SS, United Kingdom
-
Leeds Teaching Hospitals NHS Trust
RECRUITINGLeeds, LS9 7LP, United Kingdom
-
University College London Hospital
RECRUITINGLondon, NW1 2BU, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, SO16 6HU, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MOv18 IgE (an experimental antibody designed to target cancer cells)
What this could lead to
If it works, this could lead to a new treatment option for certain hard-to-treat cancers like platinum-resistant ovarian cancer.
What could go wrong
This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety and dosing. The drug may not show enough anti-tumor activity or could cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.